
Quarterly report 2025-Q2
added 08-29-2025
Agilent Technologies EPS Ratio 2011-2025 | A
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Agilent Technologies
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|
3.98 | 2.33 | 3.41 | 0.98 | 2.12 | 1.42 | 1.2 | 1.65 | 2.15 | 3.31 | 2.92 |
All numbers in USD currency
Indicator range from annual reports
Maximum | Minimum | Average |
---|---|---|
3.98 | 0.98 | 2.32 |
Quarterly EPS Ratio Agilent Technologies
2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1.18 | 1.12 | - | 0.97 | 1.19 | 1.02 | 0.94 | - | - | 0.92 | 0.94 | - | 0.87 | 0.71 | 0.64 | 1.61 | 0.64 | 0.33 | 1.58 | 2.78 | 0.61 | 0.57 | -0.99 | 0.38 | 0.74 | 0.64 | 0.52 | 1.57 | 0.55 | 0.51 | 0.37 | 1.03 | 0.38 | 0.28 | 0.19 | 0.78 | 0.33 | 0.26 | 0.59 | 1.44 | 0.44 | 0.42 | 0.52 | 1.49 | 0.5 | 0.48 | 0.66 | 2.09 | 0.7 | 0.73 | 0.56 | 2.08 | 0.95 | 0.58 |
All numbers in USD currency
Indicator range from quarterly reporting
Maximum | Minimum | Average |
---|---|---|
2.78 | -0.99 | 0.808 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
---|---|---|---|---|---|---|
![]() |
Danaher Corporation
DHR
|
5.33 | $ 204.96 | -1.82 % | $ 150 B | ![]() |
![]() |
Centogene N.V.
CNTG
|
-2.06 | $ 0.33 | -6.23 % | $ 30.6 M | ![]() |
![]() |
Global Cord Blood Corporation
CO
|
4.12 | $ 2.99 | - | $ 399 M | ![]() |
![]() |
Genetron Holdings Limited
GTH
|
-1.08 | $ 4.03 | 0.12 % | $ 80.1 M | ![]() |
![]() |
Lantheus Holdings
LNTH
|
4.52 | $ 53.55 | 3.3 % | $ 3.71 B | ![]() |
![]() |
Chembio Diagnostics
CEMI
|
-0.72 | $ 0.46 | 0.22 % | $ 16.8 M | ![]() |
![]() |
Medpace Holdings
MEDP
|
13.1 | $ 531.0 | -0.16 % | $ 16.4 B | ![]() |
![]() |
Meridian Bioscience
VIVO
|
0.97 | $ 33.97 | - | $ 1.49 B | ![]() |
![]() |
HTG Molecular Diagnostics
HTGM
|
-24.3 | $ 0.48 | -20.0 % | $ 1.06 M | ![]() |
![]() |
Neogen Corporation
NEOG
|
-5.03 | $ 5.82 | 4.11 % | $ 1.26 B | ![]() |
![]() |
Quotient Limited
QTNT
|
-1.21 | $ 0.32 | -11.32 % | $ 1.1 M | ![]() |
![]() |
Pacific Biosciences of California
PACB
|
-1.21 | $ 1.51 | 7.86 % | $ 383 M | ![]() |
![]() |
Bioventus
BVS
|
-2.49 | $ 6.76 | 1.65 % | $ 423 M | ![]() |
![]() |
Heska Corporation
HSKA
|
-1.92 | $ 119.99 | - | $ 1.31 B | ![]() |
![]() |
Twist Bioscience Corporation
TWST
|
-3.6 | $ 32.79 | 5.37 % | $ 1.9 B | ![]() |
![]() |
Motus GI Holdings
MOTS
|
-15.9 | $ 0.17 | -34.28 % | $ 263 K | ![]() |
![]() |
Biocept
BIOC
|
-1.89 | $ 0.43 | -13.05 % | $ 7.29 M | ![]() |
![]() |
VolitionRx Limited
VNRX
|
-0.45 | $ 0.65 | -0.31 % | $ 62.5 M | ![]() |
![]() |
Syneos Health
SYNH
|
2.26 | $ 42.98 | - | $ 4.46 B | ![]() |
![]() |
Invitae Corporation
NVTA
|
-13.2 | $ 0.09 | - | $ 21.2 M | ![]() |
![]() |
DermTech
DMTK
|
-3.09 | $ 0.09 | -11.32 % | $ 2.94 M | ![]() |
![]() |
Akumin
AKU
|
-1.75 | $ 0.29 | -17.87 % | $ 25.9 M | ![]() |
![]() |
Castle Biosciences
CSTL
|
0.66 | $ 23.59 | 2.92 % | $ 655 M | ![]() |
![]() |
DarioHealth Corp.
DRIO
|
1.93 | $ 16.37 | 5.27 % | $ 464 M | ![]() |
![]() |
Brainsway Ltd.
BWAY
|
-0.24 | $ 15.53 | 1.94 % | $ 99.4 M | ![]() |
![]() |
PerkinElmer
PKI
|
2.21 | $ 115.24 | -0.91 % | $ 14.7 B | ![]() |
![]() |
OpGen
OPGN
|
2.44 | $ 1.96 | -16.95 % | $ 1.54 M | ![]() |
![]() |
Guardant Health
GH
|
-3.56 | $ 65.32 | 2.96 % | $ 8.02 B | ![]() |
![]() |
DexCom
DXCM
|
1.4 | $ 67.78 | 2.65 % | $ 26.2 B | ![]() |
![]() |
Organovo Holdings
ONVO
|
-1.7 | $ 2.12 | -2.3 % | $ 19.4 M | ![]() |
![]() |
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 8.82 | -2.17 % | $ 94.9 M | ![]() |
![]() |
Biomerica
BMRA
|
-2.16 | $ 2.88 | 1.41 % | $ 6.62 M | ![]() |
![]() |
Fulgent Genetics
FLGT
|
-1.41 | $ 22.83 | 0.88 % | $ 690 M | ![]() |
![]() |
Psychemedics Corporation
PMD
|
-0.72 | $ 2.67 | -1.84 % | $ 15.3 M | ![]() |
![]() |
Genetic Technologies Limited
GENE
|
-0.08 | $ 0.77 | - | $ 7.1 B | ![]() |
![]() |
Myriad Genetics
MYGN
|
-1.41 | $ 7.64 | 1.46 % | $ 692 M | ![]() |
![]() |
Renalytix AI plc
RNLX
|
-0.31 | $ 0.21 | 5.66 % | $ 22.7 M | ![]() |
![]() |
CareDx, Inc
CDNA
|
-3.54 | $ 14.79 | 0.82 % | $ 795 M | ![]() |
![]() |
IQVIA Holdings
IQV
|
7.57 | $ 200.6 | -0.13 % | $ 36.4 B | ![]() |
![]() |
Koninklijke Philips N.V.
PHG
|
3.67 | $ 28.25 | 1.51 % | $ 20 B | ![]() |
![]() |
Biodesix
BDSX
|
-0.33 | $ 7.75 | 6.16 % | $ 1 B | ![]() |
![]() |
T2 Biosystems
TTOO
|
-19.2 | $ 0.12 | -39.35 % | $ 313 K | ![]() |
![]() |
Co-Diagnostics
CODX
|
-1.2 | $ 0.39 | 5.12 % | $ 11.4 M | ![]() |
![]() |
Celcuity
CELC
|
-2.83 | $ 49.5 | 0.58 % | $ 1.95 B | ![]() |